We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cardinal Health to Collaborate with Wyeth on Cell Line Development

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cardinal Health to Collaborate with Wyeth on Cell Line Development "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cardinal Health has announced it has entered a feasibility agreement with Wyeth, acting through its Wyeth Pharmaceuticals division, to develop cell lines using Cardinal Health’s Gene Product Expression (GPEx®) cell line engineering technology. 

Cardinal Health will use its patented GPEx® technology to engineer cell lines that express two undisclosed biopharmaceutical molecules in experiments that will determine if the GPEx® approach is a feasible augmentation to Wyeth’s current production methods.

"Wyeth has taken a leadership position among major pharmaceutical companies to seriously move into large molecule therapeutics and has a great track record with biopharmaceutical R&D, manufacturing and commercialization," said Paul Weiss, PhD, president of Cardinal Health’s biopharmaceutical development services center.

"We feel confident that the speed and high expression capabilities of our GPEx® technology will be attractive to Wyeth as they evaluate additional platforms to rapidly and cost-effectively produce biopharmaceuticals."